Audentes Therapeutics Inc

Most Recent

  • uploads///BMRN ana reco
    Company & Industry Overviews

    Analysts Remain Bullish on BioMarin Pharmaceutical

    Of the 23 analysts covering BioMarin Pharmaceutical (BMRN) in September, 19 of them have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Audentes Therapeutics’ Promising Product Pipeline

    In this series, we’ll take a look at six stocks with a focus on gene therapy that have promising products in their pipelines.

    By Kenneth Smith
  • uploads///Audentes ana reco
    Company & Industry Overviews

    Analyzing Audentes Therapeutics’ Valuation Metrics

    Audentes Therapeutics (BOLD) incurred a net loss of $31.37 million in the second quarter compared with $22.74 million in Q2 2017.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.